C-PZHXGC Therapeutics
iPSC cell therapy, cellular programming, gene editing
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PZHX
C-PZHXC-PZHXiPSC cell therapy, cellular programming, gene editing
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Alex Ng Bio — GC Therapeutics 0 Skip to Content Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News Alex Ng Chief Innovation Officer & Co-Founder Alex Ng is a co-founder and chief innovation officer at GCTx, and co-invented GCTx’s core TFome™ technology. Alex is a pioneer in cell programming technologies and has developed many core synthetic biology approaches that have been published in prestigious peer-reviewed journals including Nature, Science and Cell family publications. With over … e received numerous awards and fellowships, including the Templeton Independent Fellowship, Carolyn & Peter Lynch Fellowship and NSERC Alexander Graham Bell Fellowship, and has been featured by media outlets such as CBS’s 60 Minutes, ABC news, Der Spiegel, Nature Biotechnology, Harvard Gazette, among others. He is a Canadian raised in Vancouver, BC and graduated from the University of British Columbia with a BSc(Hons) in biochemistry and statistics. He moved to Cambridge, … of. George Church, where he co-invented the TFome™ technology, and postdoctoral fellowship with Prof. Michael Elowitz at Caltech. Back to About Us Contact Us © 2025 GC Therapeutics, Inc. All rights reserved.
#lifesciences #innovation #leadership #biotech #lifesciencessummit #gctx | Parastoo Khoshakhlagh, Ph.D. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag
Instagram Instagram Log In Sign Up Close Never miss a post from labcentral.inc Sign up for Instagram to stay in the loop. Sign up Log in labcentral.inc • Follow More options labcentral.inc 33w It’s time to Dish! 🧫🔬 Johannes Fruehauf sits down with Parastoo Khoshakhlagh, Ph.D., CEO & co-founder of GC Therapeutics, to talk turning loss into innovation, making cell therapies accessible, and using AI to push biotech’s boundaries. Catch the full story at the 🔗 in our bio! Load more comments No comments yet. Start the conversation. Like Comment Share Save October 21, 2025 Log in to like or co
AIAP San Diego - General Meeting: "How To Translate Science Into A Revolutionary Business" by Dr. Parastoo Khoshakhlagh Association of Iranian American Professionals Log in Home Partners About Our Mission Charity Committee Bylaws Board of Directors Board of Advisory Financial Statement Events Upcoming Events Past Events Survey Results Disclaimers Membership Become a new Member Renew Membership Mobile App Photos & Videos Community Outreach Donate Donate to AIAP Donate to San Diego Food Bank Scholarship Sponsorship Sponsorship Plans Jobs Contact Us Join Our Email List Home General … ol and co-authored in Nature Biotechnology. GCTx’s she completed a postdoctoral fellowship in the laboratory of Dr. Ali Khademhosseini at the Harvard-MIT Division of Health Sciences and Technology. Dr. Khoshakhlagh is also the co-founder, co-inventor and former CSO of Tympanogen, Inc., a woman-led company which is developing Perf-Fix, the first non-surgical, minimally invasive 3D hydrogel patch to heal chronic eardrum ruptures. Tympanogen has won multiple national and interna … and international awards such as the NASA Earth / Space Life Science Innovation Award and the nCourage Courageous Women Entrepreneur Prize. She completed her Ph.D. in Biomedical Engineering at Tulane University. Her work during her PhD led to her being a co-inventor on a U.S. patent application that resulted in the creation of Axosim, a start-up that develops drug screening nerve-on-a-chip products. Dr. Khoshakhlagh will present in English . Even though the time provided for
Alex Ng | SynBioBeta Speaker Γ SynBioBeta Speaker Alex Ng Chief Scientific Officer & Co-Founder GC Therapeutics Dr. Alex Ng is a co-founder and Chief Scientific Officer at GCTx, and co-invented GCTx’s core TFome™ technology. He is a pioneer in cell programming technologies and has developed many core synthetic biology approaches that have been published in prestigious peer-reviewed journals including Nature, Science and Cell family publications. With over a decade of experience in the field of synthetic biology and stem cells, he is a co-inventor on many issued or pending patents and has b … e received numerous awards and fellowships, including the Templeton Independent Fellowship, Carolyn & Peter Lynch Fellowship and NSERC Alexander Graham Bell Fellowship and has been featured by media outlets such as CBS’s 60 Minutes, ABC News, Der Spiegel, Nature Biotechnology, Harvard Gazette, among others. He is a Canadian raised in Vancouver, BC and graduated from the University of British Columbia with a BSc(Hons) in biochemistry and statistics. He moved to Cambridge, … f. George Church, where he co-invented the TFome™ technology, and post-doctoral fellowship with Prof. Michael Elowitz at Caltech. SynBioBeta 2025 - Session Speaker AI 'Cheat Codes' Speed Therapeutic Cell Creation via Transcription Factors One of the biggest challenges faced by the regenerative medicine field today is the ability to efficiently and scalably generate therapeutic cells. This session explores cutting-edge transcription factor-based approaches for rapid and effic
GC Therapeutics Appoints Stem Cell Therapy Leader Stefan Irion, MD, as Chief Scientific Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases GC Therapeutics Appoints Stem Cell Therapy Leader Stefan Irion, MD, as Chief Scientific Officer May 5, 2026 | 6 min read Twitter LinkedIn Facebook Email Print CAMBRIDGE, Mass.--(BUSINESS WIRE)--GC Therapeutics (GCTx), a pioneering biotechnology company advancing the next generation of cell-based medicines … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
GCTx Taps Haviland as Chair, Unveils AI-Powered Cell Therapy Pipeline - BriefGlance.com Skip to main content BriefGlance.com INTELLIGENCE Intelligence Market pulse Wire Media Center Contact Sign In Menu × Media Center Contact Wire Sign In Home Helen Davis GCTx Taps Haviland as Chair, Unveils AI-Powered Cell Therapy Pipeline GCTx Taps Haviland as Chair, Unveils AI-Powered Cell Therapy Pipeline 📊 Key Data $75 million raised to date, including a $65 million Series A round 90% efficiency in a single-step, four-day differentiation process 1.6 million Americans affected by Type 1 Diabetes, a … mark a transition from foundational platform development to focused therapeutic application, positioning GCTx as a company to watch in the rapidly evolving regenerative medicine landscape. A New Era of Strategic Leadership The appointment of Kate Haviland as Board Chair brings formidable strategic and commercial expertise to GC Therapeutics at a critical inflection point. Haviland is widely respected for her leadership at Blueprint Medicines, where she served as president and
GCTx launches with bold cell therapy claim | The Pharmaletter Sunday 14 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes … for $180 million 12 June 2026 Biotechnology Autolus wins Prix Galien UK biotech award for Aucatzyl 12 June 2026 Pharmaceutical Highlights from EMA pharmacovigilance committee meeting 12 June 2026 Biotechnology Australian biotechs say they will be worse off under RDTI changes 12 June 2026 Pharmaceutical AbbVie presents Phase III venetoclax data in first-line CLL 12 June 2026 Company Spotlight Beren Therapeutics A clinical-stage biotechnology company using a cyclodextrin platfo … s sale of PRV for $180 million 12 June 2026 Autolus wins Prix Galien UK biotech award for Aucatzyl 12 June 2026 Australian biotechs say they will be worse off under RDTI changes 12 June 2026 The Pharma Letter 39-43 Putney High Street, Putney London, SW15 1SP United Kingdom About us Contact Subscribe Sponsorship/advertising Company News Directory Terms and Conditions Privacy Policy Twitter Linkedin Copyright © The Pharma Letter 2026 | Headless Content Management with Blaze
About Us — GC Therapeutics 0 Skip to Content Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News About Us Invented and developed by a world-class team of scientists in the lab of George Church, Ph.D., at the Wyss Institute of Harvard University, GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome™, integrates the latest advancements in synthetic biology, gene editing, cell engineering and machine learning to overcome the development and scaling complexities associated with cell
GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy — GC Therapeutics 0 Skip to Content Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy Press Releases Sep 19 Written By Lisa Barker GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy TFome™, the world’s first “plug-and-play” iPSC cellular programming platform, streamlines developmen
GC Therapeutics 0 Skip to Content Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News Open Menu Close Menu Our Science About Us Careers News Empowering SuperCells™. Restoring Hope. Cell Therapy Meets Unprecedented Scalability GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome ), to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of th